SCHEMBL17830713

SCHEMBL17830713

O=C(CN1C(=O)Cc2cc(Cl)ccc21)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.44
HTT P42858 1/20 0.44
GRM5 P41594 1/20 0.44
GPBAR1 Q8TDU6 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 2/20 0.42
PTGDR2 Q9Y5Y4 4/20 0.42
NOTUM Q6P988 1/20 0.41
CCKBR P32239 1/20 0.41
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15157067 0.85 NOTUM (0.52) L3MBTL1SMN1; SMN2MAPTALDH1A1MAPK1
SCHEMBL12571561 0.83 HTT (0.62) USP2HTTSMN1; SMN2LMNAMAPT
SCHEMBL2482539 0.81 P2RX4 (0.48) GRM5GPBAR1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL12205220 0.81 CCKBR (0.44) ALDH1A1PTGDR2CCKBRMEN1KMT2A
SCHEMBL10691899 0.81 SMN1; SMN2 (0.46) SMN1; SMN2LMNAMAPTALDH1A1NOTUM
SCHEMBL2009991 0.80 PTGDR2 (0.49) PTGDR2CYP1A2
SCHEMBL17830710 0.78 ALDH1A1 (0.64) MAPTALDH1A1CCKBRPOLBKMT2A
SCHEMBL661498 0.77 KMT2A (0.47) HTTSMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL29868599 0.77 KMT2A (0.47) HTTSMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL17830714 0.76 PTGDR2 (0.51) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A USP2 2467/4885HTT 3243/4885GRM5 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.